These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22237841)

  • 1. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification.
    Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):543. PubMed ID: 22237841
    [No Abstract]   [Full Text] [Related]  

  • 2. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
    Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
    Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S
    Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy.
    Gains JE; Aldridge MD; Mattoli MV; Bomanji JB; Biassoni L; Shankar A; Gaze MN
    Nucl Med Commun; 2020 Nov; 41(11):1169-1177. PubMed ID: 32796449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience.
    Win Z; Al-Nahhas A; Towey D; Todd JF; Rubello D; Lewington V; Gishen P
    Nucl Med Commun; 2007 May; 28(5):359-63. PubMed ID: 17414885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
    Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT imaging in neuroblastoma.
    Piccardo A; Lopci E; Conte M; Foppiani L; Garaventa A; Cabria M; Villavecchia G; Fanti S; Cistaro A
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):29-39. PubMed ID: 23474633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model.
    Cuccurullo V; Mansi L
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1262-5. PubMed ID: 22644715
    [No Abstract]   [Full Text] [Related]  

  • 9. A rare case of a
    Kroiss AS; Uprimny C; Pichler R; Gasser RW; Virgolini IJ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(5):315-317. PubMed ID: 30042056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
    Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A
    Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
    Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
    Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
    Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
    Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
    Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report.
    Grassi I; Nanni C; Vicennati V; Castellucci P; Allegri V; Montini GC; Pagotto U; di Dalmazi G; Pasquali R; Fanti S
    Clin Nucl Med; 2011 Feb; 36(2):124-6. PubMed ID: 21220975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 99mTc-HYNIC octreotide in neuroblastoma.
    Gambini JP; López Lerena JJ; Quagliata A; Hermida JC; Heuguerot C; Alonso O
    Ann Nucl Med; 2008 Nov; 22(9):817-9. PubMed ID: 19039561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study.
    Naswa N; Sharma P; Nazar AH; Agarwal KK; Kumar R; Ammini AC; Malhotra A; Bal C
    Eur Radiol; 2012 Mar; 22(3):710-9. PubMed ID: 21971823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
    Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
    Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.